Molecular Weight:   | 196.07 |
Volume:   | 191.655 |
LogP:   | 0.268 |
LogD:   | 0.942 |
LogS:   | -1.434 |
# Rotatable Bonds:   | 3 |
TPSA:   | 62.22 |
# H-Bond Aceptor:   | 4 |
# H-Bond Donor:   | 2 |
# Rings:   | 2 |
# Heavy Atoms:   | 4 |
QED Drug-Likeness Score:   | 0.703 |
Synthetic Accessibility Score:   | 2.925 |
Fsp3:   | 0.4 |
Lipinski Rule-of-5:   | Accepted |
Pfizer Rule:   | Accepted |
GSK Rule:   | Accepted |
BMS Rule:   | 1 |
Golden Triangle Rule:   | Rejected |
Chelating Alert:   | 1 |
PAINS Alert:   | 0 |
Caco-2 Permeability:   | -4.568 |
MDCK Permeability:   | 2.0203853637212887e-05 |
Pgp-inhibitor:   | 0.0 |
Pgp-substrate:   | 0.01 |
Human Intestinal Absorption (HIA):   | 0.014 |
20% Bioavailability (F20%):   | 0.005 |
30% Bioavailability (F30%):   | 0.007 |
Blood-Brain-Barrier Penetration (BBB):   | 0.308 |
Plasma Protein Binding (PPB):   | 41.38158416748047% |
Volume Distribution (VD):   | 1.093 |
Pgp-substrate:   | 48.01060485839844% |
CYP1A2-inhibitor:   | 0.131 |
CYP1A2-substrate:   | 0.576 |
CYP2C19-inhibitor:   | 0.039 |
CYP2C19-substrate:   | 0.759 |
CYP2C9-inhibitor:   | 0.021 |
CYP2C9-substrate:   | 0.625 |
CYP2D6-inhibitor:   | 0.026 |
CYP2D6-substrate:   | 0.735 |
CYP3A4-inhibitor:   | 0.074 |
CYP3A4-substrate:   | 0.31 |
Clearance (CL):   | 12.368 |
Half-life (T1/2):   | 0.827 |
hERG Blockers:   | 0.014 |
Human Hepatotoxicity (H-HT):   | 0.196 |
Drug-inuced Liver Injury (DILI):   | 0.103 |
AMES Toxicity:   | 0.606 |
Rat Oral Acute Toxicity:   | 0.365 |
Maximum Recommended Daily Dose:   | 0.028 |
Skin Sensitization:   | 0.529 |
Carcinogencity:   | 0.768 |
Eye Corrosion:   | 0.004 |
Eye Irritation:   | 0.747 |
Respiratory Toxicity:   | 0.128 |
Natural Product ID:   | NPC209560 |
Common Name*:   | Formononetin |
IUPAC Name:   | 7-hydroxy-3-(4-methoxyphenyl)chromen-4-one |
Synonyms:   | NSC-93360 |
Standard InCHIKey:   | HKQYGTCOTHHOMP-UHFFFAOYSA-N |
Standard InCHI:   | InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)14-9-20-15-8-11(17)4-7-13(15)16(14)18/h2-9,17H,1H3 |
SMILES:   | COc1ccc(cc1)c1coc2c(c1=O)ccc(c2)O |
Synthetic Gene Cluster:   | n.a. |
ChEMBL Identifier:   | CHEMBL242341 |
PubChem CID:   |
5280378 |
Chemical Classification**:   |
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Organism ID | NP ID | Organism Material Preparation | Organism Part | NP Quantity (Standard) | NP Quantity (Minimum) | NP Quantity (Maximum) | Quantity Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPO7635 | NPC209560 | Cooked | n.a. | 6.159999847 | n.a. | n.a. | mg/100g | Database [PHENOL EXPLORER] |
NPO7635 | NPC209560 | Dried Or Powder | n.a. | 0.0167 | n.a. | n.a. | mg/100g | Database [PHENOL EXPLORER] |
NPO454 | NPC209560 | Other | n.a. | 0.025 | n.a. | n.a. | mg/100g | Database [PHENOL EXPLORER] |
NPO7635 | NPC209560 | n.a. | Seeds | 6.16 | n.a. | n.a. | mg/100g of FW | Database [Phenol-Explorer] |
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT1603 | Individual Protein | Cytochrome P450 1A1 | Homo sapiens | IC50 | < | 100000.0 | nM | PMID[558535] |
NPT517 | Cell Line | Panel NCI-60 (60 carcinoma cell lines) | Homo sapiens | GI50 | = | 50000.0 | nM | PMID[558535] |
NPT393 | Cell Line | HCT-116 | Homo sapiens | GI50 | = | 64000.0 | nM | PMID[558535] |
NPT139 | Cell Line | HT-29 | Homo sapiens | GI50 | = | 74000.0 | nM | PMID[558535] |
NPT784 | Cell Line | MDA-MB-468 | Homo sapiens | GI50 | = | 27200.0 | nM | PMID[558535] |
NPT83 | Cell Line | MCF7 | Homo sapiens | GI50 | = | 81400.0 | nM | PMID[558535] |
NPT640 | Individual Protein | Sodium/glucose cotransporter 1 | Homo sapiens | Inhibition | < | 25.0 | % | PMID[558536] |
NPT641 | Individual Protein | Sodium/glucose cotransporter 2 | Homo sapiens | Inhibition | = | 75.4 | % | PMID[558536] |
NPT466 | Cell Line | U-937 | Homo sapiens | IC50 | = | 50000.0 | nM | PMID[558537] |
NPT466 | Cell Line | U-937 | Homo sapiens | IC50 | = | 44000.0 | nM | PMID[558537] |
NPT466 | Cell Line | U-937 | Homo sapiens | IC50 | = | 45000.0 | nM | PMID[558537] |
NPT461 | Cell Line | PANC-1 | Homo sapiens | CD100 | > | 100.0 | uM | PMID[558538] |
NPT1310 | Individual Protein | Xanthine dehydrogenase | Bos taurus | Inhibition | = | 17.6 | % | PMID[558540] |
NPT165 | Cell Line | HeLa | Homo sapiens | Inhibition | = | 34.5 | % | PMID[558542] |
NPT80 | Cell Line | Raji | Homo sapiens | Activity | = | 100.0 | % | PMID[558542] |
NPT80 | Cell Line | Raji | Homo sapiens | Activity | > | 80.0 | % | PMID[558542] |
NPT80 | Cell Line | Raji | Homo sapiens | Activity | = | 20.0 | % | PMID[558542] |
NPT81 | Cell Line | A549 | Homo sapiens | IC50 | > | 100000.0 | nM | PMID[558549] |
NPT165 | Cell Line | HeLa | Homo sapiens | IC50 | > | 100000.0 | nM | PMID[558549] |
NPT453 | Cell Line | HT-1080 | Homo sapiens | IC50 | > | 100000.0 | nM | PMID[558549] |
NPT81 | Cell Line | A549 | Homo sapiens | ED50 | = | 2.87 | ug ml-1 | PMID[558550] |
NPT83 | Cell Line | MCF7 | Homo sapiens | ED50 | = | 1.96 | ug ml-1 | PMID[558550] |
NPT139 | Cell Line | HT-29 | Homo sapiens | ED50 | = | 6.43 | ug ml-1 | PMID[558550] |
NPT493 | Individual Protein | Neuraminidase | Influenza A virus | IC50 | > | 100000.0 | nM | PMID[558553] |
NPT396 | Cell Line | T47D | Homo sapiens | Activity | = | 0.01 | uM | PMID[558556] |
NPT83 | Cell Line | MCF7 | Homo sapiens | Activity | = | 0.01 | uM | PMID[558556] |
NPT396 | Cell Line | T47D | Homo sapiens | Activity | > | 100.0 | uM | PMID[558556] |
NPT396 | Cell Line | T47D | Homo sapiens | Activity | = | 0.03 | uM | PMID[558556] |
NPT83 | Cell Line | MCF7 | Homo sapiens | Activity | > | 100.0 | uM | PMID[558556] |
NPT149 | Individual Protein | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Homo sapiens | Potency | = | 39810.7 | nM | PMID[558559] |
NPT48 | Individual Protein | Lysine-specific demethylase 4D-like | Homo sapiens | Potency | = | 31622.8 | nM | PMID[558559] |
NPT149 | Individual Protein | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Homo sapiens | Potency | = | 31622.8 | nM | PMID[558560] |
NPT48 | Individual Protein | Lysine-specific demethylase 4D-like | Homo sapiens | Potency | = | 28183.8 | nM | PMID[558560] |
NPT213 | Individual Protein | Cytochrome P450 2C19 | Homo sapiens | Potency | = | 7943.3 | nM | PMID[558561] |
NPT51 | Individual Protein | Microtubule-associated protein tau | Homo sapiens | Potency | = | 5011.9 | nM | PMID[558560] |
NPT150 | Individual Protein | Anthrax lethal factor | Bacillus anthracis | Potency | = | 12589.3 | nM | PMID[558561] |
NPT151 | Individual Protein | 15-hydroxyprostaglandin dehydrogenase [NAD+] | Homo sapiens | Potency | = | 35481.3 | nM | PMID[558559] |
NPT151 | Individual Protein | 15-hydroxyprostaglandin dehydrogenase [NAD+] | Homo sapiens | Potency | = | 25118.9 | nM | PMID[558560] |
NPT539 | Individual Protein | Cellular tumor antigen p53 | Homo sapiens | Potency | = | 3981.1 | nM | PMID[558560] |
NPT149 | Individual Protein | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Homo sapiens | Potency | = | 39810.7 | nM | PMID[558561] |
NPT539 | Individual Protein | Cellular tumor antigen p53 | Homo sapiens | Potency | = | 15848.9 | nM | PMID[558559] |
NPT539 | Individual Protein | Cellular tumor antigen p53 | Homo sapiens | Potency | = | 1584.9 | nM | PMID[558560] |
NPT109 | Individual Protein | Cytochrome P450 3A4 | Homo sapiens | Potency | = | 15848.9 | nM | PMID[558559] |
NPT110 | Individual Protein | Cytochrome P450 2D6 | Homo sapiens | Potency | = | 10000.0 | nM | PMID[558561] |
NPT212 | Individual Protein | Cytochrome P450 2C9 | Homo sapiens | Potency | = | 10.0 | nM | PMID[558561] |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 16360.1 | nM | PMID[558562] |
NPT368 | Cell Line | SN12C | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT367 | Cell Line | MDA-N | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT370 | Cell Line | NCI-H23 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT371 | Cell Line | UO-31 | Homo sapiens | GI50 | n.a. | 90573.26 | nM | PMID[558563] |
NPT369 | Cell Line | ACHN | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT116 | Cell Line | HL-60 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT90 | Cell Line | DU-145 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT374 | Cell Line | SF-539 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT373 | Cell Line | SK-MEL-5 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT375 | Cell Line | Malme-3M | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT376 | Cell Line | A498 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT111 | Cell Line | K562 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT377 | Cell Line | OVCAR-3 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT112 | Cell Line | MOLT-4 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT379 | Cell Line | HOP-62 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT380 | Cell Line | U-251 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT378 | Cell Line | NCI/ADR-RES | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT382 | Cell Line | OVCAR-5 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT381 | Cell Line | OVCAR-8 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT383 | Cell Line | SNB-19 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT82 | Cell Line | MDA-MB-231 | Homo sapiens | GI50 | n.a. | 11297.96 | nM | PMID[558563] |
NPT385 | Cell Line | SR | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT323 | Cell Line | SW-620 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT384 | Cell Line | TK-10 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT455 | Cell Line | NCI-H522 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT387 | Cell Line | M14 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT386 | Cell Line | KM12 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT388 | Cell Line | NCI-H322M | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT147 | Cell Line | SK-MEL-2 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT81 | Cell Line | A549 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT391 | Cell Line | HCC 2998 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT392 | Cell Line | SNB-75 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT148 | Cell Line | HCT-15 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT395 | Cell Line | SF-268 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT393 | Cell Line | HCT-116 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT83 | Cell Line | MCF7 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT306 | Cell Line | PC-3 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT146 | Cell Line | SK-OV-3 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT396 | Cell Line | T47D | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT397 | Cell Line | NCI-H460 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT398 | Cell Line | UACC-62 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT400 | Cell Line | MDA-MB-435 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT308 | Cell Line | CAKI-1 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT458 | Cell Line | IGROV-1 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT399 | Cell Line | SF-295 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT402 | Cell Line | Hs-578T | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT403 | Cell Line | UACC-257 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT401 | Cell Line | 786-0 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT404 | Cell Line | CCRF-CEM | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT405 | Cell Line | NCI-H226 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT170 | Cell Line | SK-MEL-28 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT139 | Cell Line | HT-29 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT407 | Cell Line | COLO 205 | Homo sapiens | GI50 | n.a. | 100000.0 | nM | PMID[558563] |
NPT519 | Cell Line | SH-SY5Y | Homo sapiens | IC50 | > | 100000.0 | nM | PMID[558564] |
NPT165 | Cell Line | HeLa | Homo sapiens | IC50 | = | 8510.0 | nM | PMID[558564] |
NPT515 | Cell Line | SGC-7901 | Homo sapiens | IC50 | = | 2170.0 | nM | PMID[558564] |
NPT90 | Cell Line | DU-145 | Homo sapiens | IC50 | > | 100000.0 | nM | PMID[558564] |
NPT393 | Cell Line | HCT-116 | Homo sapiens | IC50 | = | 60970.0 | nM | PMID[558564] |
NPT100 | Individual Protein | Glutaminase kidney isoform, mitochondrial | Homo sapiens | Potency | n.a. | 31622.8 | nM | PMID[558562] |
NPT157 | Individual Protein | Breast cancer type 1 susceptibility protein | Homo sapiens | Potency | n.a. | 2238.7 | nM | PMID[558562] |
NPT66 | Individual Protein | Acetylcholinesterase | Electrophorus electricus | Inhibition | = | 1.62 | % | PMID[558566] |
NPT106 | Individual Protein | Peroxisome proliferator-activated receptor delta | Homo sapiens | FC | = | 12.2 | n.a. | PMID[558567] |
NPT106 | Individual Protein | Peroxisome proliferator-activated receptor delta | Homo sapiens | FC | = | 7.4 | n.a. | PMID[558567] |
NPT493 | Individual Protein | Neuraminidase | Influenza A virus | Ratio IC50 | = | 10.0 | n.a. | PMID[558572] |
NPT616 | Cell Line | MDCK | Canis lupus familiaris | CC50 | = | 123000.0 | nM | PMID[558572] |
NPT493 | Individual Protein | Neuraminidase | Influenza A virus | IC50 | = | 5040.0 | nM | PMID[558572] |
NPT493 | Individual Protein | Neuraminidase | Influenza A virus | IC50 | = | 3040.0 | nM | PMID[558572] |
NPT493 | Individual Protein | Neuraminidase | Influenza A virus | IC50 | = | 1370.0 | nM | PMID[558572] |
NPT535 | Individual Protein | Parathyroid hormone receptor | Homo sapiens | Potency | n.a. | 112201.8 | nM | PMID[558562] |
NPT2956 | Individual Protein | Interleukin-2 | Homo sapiens | Kd | = | 5470.0 | nM | PMID[558576] |
NPT65 | Cell Line | HepG2 | Homo sapiens | IC50 | = | 60500.0 | nM | PMID[558576] |
NPT34 | Cell Line | BV-2 | Mus musculus | IC50 | > | 100000.0 | nM | PMID[558582] |
NPT848 | Cell Line | N9 | Homo sapiens | IC50 | > | 100000.0 | nM | PMID[558584] |
NPT306 | Cell Line | PC-3 | Homo sapiens | IC50 | = | 57010.0 | nM | PMID[558585] |
NPT5186 | Cell Line | ECa-109 cell line | IC50 | > | 100000.0 | nM | PMID[558585] | |
NPT3140 | Cell Line | MGC-803 | Homo sapiens | IC50 | > | 100000.0 | nM | PMID[558585] |
NPT1604 | Individual Protein | Cytochrome P450 1B1 | Homo sapiens | Ki | = | 3700.0 | nM | PMID[558586] |
NPT83 | Cell Line | MCF7 | Homo sapiens | GI | = | 2.0 | % | PMID[558587] |
NPT660 | Cell Line | SW480 | Homo sapiens | GI | = | 4.0 | % | PMID[558587] |
NPT65 | Cell Line | HepG2 | Homo sapiens | GI | = | 0.0 | % | PMID[558587] |
NPT113 | Cell Line | RAW264.7 | Mus musculus | Inhibition | = | 0.0 | % | PMID[558587] |
NPT178 | Individual Protein | Protein-tyrosine phosphatase 1B | Homo sapiens | Inhibition | = | 33.0 | % | PMID[558587] |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | FC | = | 2.65 | n.a. | PMID[558588] |
NPT34 | Cell Line | BV-2 | Mus musculus | IC50 | = | 13190.0 | nM | PMID[558589] |
NPT178 | Individual Protein | Protein-tyrosine phosphatase 1B | Homo sapiens | Inhibition | = | 9.9 | % | PMID[558590] |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | FC | = | 2.0 | n.a. | PMID[558590] |
NPT113 | Cell Line | RAW264.7 | Mus musculus | Inhibition | = | 0.0 | % | PMID[558590] |
NPT65 | Cell Line | HepG2 | Homo sapiens | Inhibition | = | 8.2 | % | PMID[558590] |
NPT81 | Cell Line | A549 | Homo sapiens | Inhibition | = | 15.4 | % | PMID[558590] |
NPT83 | Cell Line | MCF7 | Homo sapiens | Inhibition | = | 51.8 | % | PMID[558590] |
NPT660 | Cell Line | SW480 | Homo sapiens | Inhibition | = | 0.0 | % | PMID[558590] |
NPT1603 | Individual Protein | Cytochrome P450 1A1 | Homo sapiens | Inhibition | = | 10.8 | % | PMID[558591] |
NPT1604 | Individual Protein | Cytochrome P450 1B1 | Homo sapiens | Inhibition | = | -1.3 | % | PMID[558591] |
NPT34 | Cell Line | BV-2 | Mus musculus | IC50 | > | 50000.0 | nM | PMID[558592] |
NPT542 | Individual Protein | Progesterone receptor | Homo sapiens | Inhibition | > | 90.0 | % | PMID[558593] |
NPT542 | Individual Protein | Progesterone receptor | Homo sapiens | Activity | = | 57.0 | % | PMID[558593] |
NPT582 | Individual Protein | Monoamine oxidase B | Homo sapiens | IC50 | = | 25800.0 | nM | PMID[558595] |
NPT261 | Individual Protein | Monoamine oxidase A | Homo sapiens | IC50 | = | 31200.0 | nM | PMID[558595] |
NPT1187 | Individual Protein | Proteasome Macropain subunit MB1 | Homo sapiens | IC50 | > | 100000.0 | nM | PMID[558596] |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | n.a. | 6164.5 | nM | PubChem BioAssay data set |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | n.a. | 6859 | nM | PubChem BioAssay data set |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 21689.9 | nM | PubChem BioAssay data set |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | n.a. | 19493.8 | nM | PubChem BioAssay data set |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | n.a. | 34376.2 | nM | PubChem BioAssay data set |
NPT163 | Individual Protein | Nuclear factor NF-kappa-B p105 subunit | Homo sapiens | Potency | n.a. | 61644.8 | nM | PubChem BioAssay data set |
NPT16 | Organism | Staphylococcus aureus | Staphylococcus aureus | MIC | > | 100.0 | ug.mL-1 | PMID[558539] |
NPT79 | Organism | Bacillus subtilis | Bacillus subtilis | MIC | > | 100.0 | ug.mL-1 | PMID[558539] |
NPT19 | Organism | Escherichia coli | Escherichia coli | MIC | = | 100.0 | ug.mL-1 | PMID[558539] |
NPT20 | Organism | Candida albicans | Candida albicans | MIC | > | 100.0 | ug.mL-1 | PMID[558539] |
NPT3086 | Organism | Penicillium expansum | Penicillium expansum | MIC | = | 50.0 | ug.mL-1 | PMID[558539] |
NPT21 | Organism | Aspergillus niger | Aspergillus niger | MIC | = | 100.0 | ug.mL-1 | PMID[558539] |
NPT330 | Organism | Trichophyton mentagrophytes | Trichophyton mentagrophytes | MIC | > | 100.0 | ug.mL-1 | PMID[558539] |
NPT566 | Organism | Salmonella typhimurium | Salmonella enterica subsp. enterica serovar Typhimurium | Inhibition | = | 0.0 | % | PMID[558541] |
NPT2 | Others | Unspecified | Activity | = | 0.0 | % | PMID[558542] | |
NPT2 | Others | Unspecified | Activity | = | 100.0 | % | PMID[558542] | |
NPT2 | Others | Unspecified | Activity | = | 92.6 | % | PMID[558542] | |
NPT2 | Others | Unspecified | Activity | = | 63.6 | % | PMID[558542] | |
NPT2645 | Organism | Giardia intestinalis | Giardia intestinalis | IC50 | < | 1.0 | ug.mL-1 | PMID[558543] |
NPT2645 | Organism | Giardia intestinalis | Giardia intestinalis | IC50 | = | 0.03 | ug.mL-1 | PMID[558543] |
NPT2645 | Organism | Giardia intestinalis | Giardia intestinalis | Activity | = | 0.1 | n.a. | PMID[558543] |
NPT2 | Others | Unspecified | IC50 | = | 700000.0 | nM | PMID[558548] | |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | IC50 | = | 83600.0 | nM | PMID[558549] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | IC50 | > | 100000.0 | nM | PMID[558549] |
NPT140 | Organism | Artemia | Artemia | LC50 | = | 22.7 | ug.mL-1 | PMID[558550] |
NPT141 | Organism | Agrobacterium tumefaciens | Agrobacterium tumefaciens | T/C | = | 79.0 | % | PMID[558550] |
NPT471 | Organism | Trypanosoma brucei brucei | Trypanosoma brucei brucei | IC50 | = | 90200.0 | nM | PMID[558552] |
NPT99 | Individual Protein | Peroxisome proliferator-activated receptor gamma | Homo sapiens | FC | = | 4.6 | n.a. | PMID[558554] |
NPT99 | Individual Protein | Peroxisome proliferator-activated receptor gamma | Homo sapiens | FC | = | 12.8 | n.a. | PMID[558554] |
NPT866 | Individual Protein | Peroxisome proliferator-activated receptor alpha | Homo sapiens | FC | = | 7.5 | n.a. | PMID[558554] |
NPT866 | Individual Protein | Peroxisome proliferator-activated receptor alpha | Homo sapiens | FC | = | 7.8 | n.a. | PMID[558554] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Activity | = | 0.11 | MU | PMID[558555] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | deltaA | = | 0.2 | n.a. | PMID[558558] |
NPT197 | Protein-Protein Interaction | Menin/Histone-lysine N-methyltransferase MLL | Homo sapiens | Potency | = | 39810.7 | nM | PMID[558559] |
NPT2 | Others | Unspecified | Potency | = | 31622.8 | nM | PMID[558560] | |
NPT2 | Others | Unspecified | Potency | = | 25118.9 | nM | PMID[558559] | |
NPT93 | Individual Protein | Survival motor neuron protein | Homo sapiens | Potency | = | 11220.2 | nM | PMID[558560] |
NPT94 | Individual Protein | Aldehyde dehydrogenase 1A1 | Homo sapiens | Potency | = | 39810.7 | nM | PMID[558559] |
NPT20798 | PROTEIN COMPLEX | GTP-binding nuclear protein Ran/Importin subunit beta-1/Snurportin-1 | Homo sapiens | Potency | n.a. | 7307.8 | nM | PMID[558562] |
NPT586 | Organism | Giardia | Giardia | Potency | n.a. | 584.8 | nM | PMID[558562] |
NPT2 | Others | Unspecified | Potency | n.a. | 5011.9 | nM | PMID[558562] | |
NPT586 | Organism | Giardia | Giardia | Potency | n.a. | 1155.4 | nM | PMID[558562] |
NPT888 | Individual Protein | 78 kDa glucose-regulated protein | Homo sapiens | Potency | n.a. | 12589.3 | nM | PMID[558562] |
NPT67 | Individual Protein | Cholinesterase | Equus caballus | Inhibition | = | 0.57 | % | PMID[558566] |
NPT22906 | PROTEIN COMPLEX | Urease subunit alpha/Urease subunit beta | Helicobacter pylori (strain ATCC 700392 / 26695) (Campylobacterpylori) | IC50 | = | 2003000.0 | nM | PMID[558568] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | IC50 | = | 56100.0 | nM | PMID[558569] |
NPT73 | Individual Protein | Solute carrier organic anion transporter family member 1B1 | Homo sapiens | Inhibition | = | 169.75 | % | PMID[558570] |
NPT72 | Individual Protein | Solute carrier organic anion transporter family member 1B3 | Homo sapiens | Inhibition | = | 114.71 | % | PMID[558570] |
NPT2645 | Organism | Giardia intestinalis | Giardia intestinalis | IC50 | = | 0.03 | ug.mL-1 | PMID[558571] |
NPT2 | Others | Unspecified | IC50 | = | 340.0 | nM | PMID[558572] | |
NPT2 | Others | Unspecified | IC50 | = | 13600.0 | nM | PMID[558572] | |
NPT35 | Others | n.a. | Activity | = | -12.4 | % | PMID[558572] | |
NPT35 | Others | n.a. | Activity | = | 15.4 | % | PMID[558572] | |
NPT742 | Organism | Influenza A virus | Influenza A virus | IC50 | = | 42600.0 | nM | PMID[558572] |
NPT742 | Organism | Influenza A virus | Influenza A virus | IC50 | = | 38200.0 | nM | PMID[558572] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Potency | n.a. | 23694.5 | nM | PMID[558573] |
NPT2 | Others | Unspecified | Potency | n.a. | 6309.6 | nM | PMID[558574] | |
NPT2 | Others | Unspecified | Potency | n.a. | 8912.5 | nM | PMID[558575] | |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Potency | n.a. | 21117.7 | nM | PMID[558573] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Potency | n.a. | 16774.4 | nM | PMID[558573] |
NPT2 | Others | Unspecified | Potency | n.a. | 562.3 | nM | PMID[558574] | |
NPT2 | Others | Unspecified | Potency | n.a. | 15848.9 | nM | PMID[558575] | |
NPT35 | Others | n.a. | Retention_time | = | 48.5 | min | PMID[558576] | |
NPT2 | Others | Unspecified | Kd | = | 7750.0 | nM | PMID[558576] | |
NPT35 | Others | n.a. | LogD7.4 | n.a. | 3.05 | n.a. | PMID[558577] | |
NPT2 | Others | Unspecified | FC | = | 1.3 | n.a. | PMID[558578] | |
NPT2 | Others | Unspecified | FC | = | 1.5 | n.a. | PMID[558578] | |
NPT2 | Others | Unspecified | FC | = | 1.2 | n.a. | PMID[558578] | |
NPT2 | Others | Unspecified | Inhibition | = | 27.1 | % | PMID[558578] | |
NPT2 | Others | Unspecified | Inhibition | = | 25.1 | % | PMID[558578] | |
NPT2 | Others | Unspecified | Inhibition | = | 9.2 | % | PMID[558578] | |
NPT2 | Others | Unspecified | Inhibition | = | 27.4 | % | PMID[558578] | |
NPT2 | Others | Unspecified | Inhibition | = | 7.1 | % | PMID[558578] | |
NPT2 | Others | Unspecified | Inhibition | = | 23.1 | % | PMID[558578] | |
NPT983 | Protein Complex | Nuclear factor NF-kappa-B complex | Homo sapiens | FC | = | 1.3 | n.a. | PMID[558578] |
NPT790 | Organism | Mycobacterium tuberculosis H37Rv | Mycobacterium tuberculosis H37Rv | GI | = | 88.0 | % | PMID[558581] |
NPT2 | Others | Unspecified | Potency | n.a. | 1412.5 | nM | PMID[558574] | |
NPT35 | Others | n.a. | IC50 | = | 62.57 | ug.mL-1 | PMID[558583] | |
NPT35 | Others | n.a. | IC50 | = | 77.42 | ug.mL-1 | PMID[558583] | |
NPT35 | Others | n.a. | IC50 | = | 43.51 | ug.mL-1 | PMID[558583] | |
NPT2 | Others | Unspecified | Inhibition | = | 3.0 | % | PMID[558587] | |
NPT2 | Others | Unspecified | Inhibition | = | 10.0 | % | PMID[558587] | |
NPT741 | Individual Protein | Tyrosinase | Homo sapiens | Inhibition | = | 4.3 | % | PMID[558590] |
NPT2 | Others | Unspecified | Inhibition | = | 0.0 | % | PMID[558590] | |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | Inhibition | = | 2.21 | % | PMID[558594] |
NPT893 | Individual Protein | Monoamine oxidase B | Mus musculus | IC50 | = | 11000.0 | nM | PMID[558595] |
NPT892 | Individual Protein | Monoamine oxidase A | Mus musculus | IC50 | = | 21200.0 | nM | PMID[558595] |
NPT2 | Others | Unspecified | Ratio IC50 | = | 1.2 | n.a. | PMID[558595] | |
NPT20556 | SINGLE PROTEIN | Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Inhibition | = | -9.57 | % | PMID[558597] |
NPT20556 | SINGLE PROTEIN | Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Inhibition | = | -33.54 | % | PMID[558598] |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | Inhibition | = | 0.14 | % | PMID[558599] |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | Inhibition | = | 0.05 | % | PMID[558600] |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | IC50 | > | 20000.0 | nM | PMID[558601] |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | IC50 | > | 19952.62 | nM | PMID[558601] |
NPT2 | Others | Unspecified | Potency | n.a. | 7760.6 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 1535.5 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 27306 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 10870.7 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 1368.5 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 6859 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 436.4 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 21872.4 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 30637.9 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 1722.9 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 43277.1 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 544.8 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 61130.6 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 485.6 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 685.9 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 8707.6 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 12197.2 | nM | PubChem BioAssay data set |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC209560 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
1.0 | High Similarity | NPC303644 |
1.0 | High Similarity | NPC7013 |
1.0 | High Similarity | NPC294409 |
1.0 | High Similarity | NPC181124 |
1.0 | High Similarity | NPC116632 |
1.0 | High Similarity | NPC162680 |
0.9924 | High Similarity | NPC55162 |
0.9924 | High Similarity | NPC278323 |
0.9924 | High Similarity | NPC279668 |
0.9924 | High Similarity | NPC12175 |
0.9924 | High Similarity | NPC309154 |
0.9924 | High Similarity | NPC90665 |
0.985 | High Similarity | NPC295384 |
0.9847 | High Similarity | NPC39426 |
0.9847 | High Similarity | NPC234560 |
0.9776 | High Similarity | NPC144118 |
0.9776 | High Similarity | NPC219917 |
0.9776 | High Similarity | NPC215311 |
0.9776 | High Similarity | NPC48624 |
0.9776 | High Similarity | NPC80962 |
0.9776 | High Similarity | NPC101366 |
0.9776 | High Similarity | NPC259166 |
0.9776 | High Similarity | NPC326109 |
0.9776 | High Similarity | NPC213659 |
0.9776 | High Similarity | NPC172250 |
0.9776 | High Similarity | NPC204985 |
0.9773 | High Similarity | NPC87545 |
0.9773 | High Similarity | NPC235428 |
0.9704 | High Similarity | NPC26051 |
0.9704 | High Similarity | NPC469404 |
0.9704 | High Similarity | NPC55832 |
0.9704 | High Similarity | NPC268204 |
0.9704 | High Similarity | NPC52789 |
0.9701 | High Similarity | NPC283429 |
0.9699 | High Similarity | NPC212767 |
0.963 | High Similarity | NPC253822 |
0.9624 | High Similarity | NPC193792 |
0.9621 | High Similarity | NPC286336 |
0.9618 | High Similarity | NPC182428 |
0.9618 | High Similarity | NPC212631 |
0.9618 | High Similarity | NPC129132 |
0.9618 | High Similarity | NPC257756 |
0.9618 | High Similarity | NPC205468 |
0.9618 | High Similarity | NPC87231 |
0.9562 | High Similarity | NPC475705 |
0.9562 | High Similarity | NPC476178 |
0.9562 | High Similarity | NPC117836 |
0.9562 | High Similarity | NPC51887 |
0.9552 | High Similarity | NPC250266 |
0.9552 | High Similarity | NPC266597 |
0.9552 | High Similarity | NPC228661 |
0.9545 | High Similarity | NPC294593 |
0.9545 | High Similarity | NPC82225 |
0.9545 | High Similarity | NPC159623 |
0.9545 | High Similarity | NPC188646 |
0.9545 | High Similarity | NPC223354 |
0.9545 | High Similarity | NPC204960 |
0.9545 | High Similarity | NPC312318 |
0.9545 | High Similarity | NPC472365 |
0.9545 | High Similarity | NPC18877 |
0.9545 | High Similarity | NPC337373 |
0.9545 | High Similarity | NPC263670 |
0.9545 | High Similarity | NPC175098 |
0.9545 | High Similarity | NPC56031 |
0.9545 | High Similarity | NPC139813 |
0.9545 | High Similarity | NPC20560 |
0.9545 | High Similarity | NPC144051 |
0.9545 | High Similarity | NPC192304 |
0.9545 | High Similarity | NPC28753 |
0.9545 | High Similarity | NPC242294 |
0.9542 | High Similarity | NPC262359 |
0.9542 | High Similarity | NPC308037 |
0.9542 | High Similarity | NPC313618 |
0.9542 | High Similarity | NPC64359 |
0.9493 | High Similarity | NPC476055 |
0.9489 | High Similarity | NPC202981 |
0.9481 | High Similarity | NPC21350 |
0.9481 | High Similarity | NPC99333 |
0.9481 | High Similarity | NPC188947 |
0.9481 | High Similarity | NPC124269 |
0.9481 | High Similarity | NPC280284 |
0.9478 | High Similarity | NPC29353 |
0.9478 | High Similarity | NPC186838 |
0.9478 | High Similarity | NPC168105 |
0.9478 | High Similarity | NPC124784 |
0.9478 | High Similarity | NPC473391 |
0.9478 | High Similarity | NPC25287 |
0.9478 | High Similarity | NPC66349 |
0.9478 | High Similarity | NPC194281 |
0.9478 | High Similarity | NPC127447 |
0.9478 | High Similarity | NPC472364 |
0.9478 | High Similarity | NPC231772 |
0.9478 | High Similarity | NPC477242 |
0.9478 | High Similarity | NPC473887 |
0.9478 | High Similarity | NPC477244 |
0.9478 | High Similarity | NPC274109 |
0.9478 | High Similarity | NPC1486 |
0.9478 | High Similarity | NPC41461 |
0.9478 | High Similarity | NPC234133 |
0.9478 | High Similarity | NPC249606 |
0.9478 | High Similarity | NPC150399 |
0.9478 | High Similarity | NPC12165 |
0.9478 | High Similarity | NPC47815 |
0.9478 | High Similarity | NPC98115 |
0.9478 | High Similarity | NPC213603 |
0.9478 | High Similarity | NPC477243 |
0.9424 | High Similarity | NPC12377 |
0.9416 | High Similarity | NPC470087 |
0.9416 | High Similarity | NPC321980 |
0.9416 | High Similarity | NPC470089 |
0.9416 | High Similarity | NPC110969 |
0.9416 | High Similarity | NPC3188 |
0.9412 | High Similarity | NPC18260 |
0.9412 | High Similarity | NPC49242 |
0.9412 | High Similarity | NPC261234 |
0.9412 | High Similarity | NPC265871 |
0.9412 | High Similarity | NPC274784 |
0.9412 | High Similarity | NPC150648 |
0.9412 | High Similarity | NPC329203 |
0.9412 | High Similarity | NPC222342 |
0.9412 | High Similarity | NPC78913 |
0.9412 | High Similarity | NPC470211 |
0.9412 | High Similarity | NPC310135 |
0.9412 | High Similarity | NPC477956 |
0.9412 | High Similarity | NPC225153 |
0.9412 | High Similarity | NPC20709 |
0.9407 | High Similarity | NPC290291 |
0.9407 | High Similarity | NPC188879 |
0.9407 | High Similarity | NPC275055 |
0.9407 | High Similarity | NPC472419 |
0.9407 | High Similarity | NPC317119 |
0.9407 | High Similarity | NPC153979 |
0.9403 | High Similarity | NPC13575 |
0.9403 | High Similarity | NPC131039 |
0.9403 | High Similarity | NPC156092 |
0.9394 | High Similarity | NPC164236 |
0.9394 | High Similarity | NPC475008 |
0.9394 | High Similarity | NPC186097 |
0.9394 | High Similarity | NPC475009 |
0.9394 | High Similarity | NPC66384 |
0.9394 | High Similarity | NPC128348 |
0.9394 | High Similarity | NPC189106 |
0.9394 | High Similarity | NPC112192 |
0.9394 | High Similarity | NPC309717 |
0.9389 | High Similarity | NPC185497 |
0.9389 | High Similarity | NPC247779 |
0.9357 | High Similarity | NPC51070 |
0.9357 | High Similarity | NPC237635 |
0.9357 | High Similarity | NPC79469 |
0.9357 | High Similarity | NPC24673 |
0.9357 | High Similarity | NPC97716 |
0.9357 | High Similarity | NPC222298 |
0.9357 | High Similarity | NPC104406 |
0.9357 | High Similarity | NPC201731 |
0.9353 | High Similarity | NPC303185 |
0.9353 | High Similarity | NPC234629 |
0.9353 | High Similarity | NPC184649 |
0.9353 | High Similarity | NPC311741 |
0.9348 | High Similarity | NPC226636 |
0.9348 | High Similarity | NPC11561 |
0.9343 | High Similarity | NPC188243 |
0.9343 | High Similarity | NPC284550 |
0.9343 | High Similarity | NPC270883 |
0.9343 | High Similarity | NPC269652 |
0.9343 | High Similarity | NPC172986 |
0.9343 | High Similarity | NPC265178 |
0.9343 | High Similarity | NPC281207 |
0.9343 | High Similarity | NPC76445 |
0.9343 | High Similarity | NPC261227 |
0.9343 | High Similarity | NPC6407 |
0.9343 | High Similarity | NPC11056 |
0.9343 | High Similarity | NPC129853 |
0.9343 | High Similarity | NPC110228 |
0.9343 | High Similarity | NPC241100 |
0.9343 | High Similarity | NPC159275 |
0.9338 | High Similarity | NPC251681 |
0.9338 | High Similarity | NPC243528 |
0.9338 | High Similarity | NPC25427 |
0.9338 | High Similarity | NPC472460 |
0.9338 | High Similarity | NPC329225 |
0.9338 | High Similarity | NPC201395 |
0.9338 | High Similarity | NPC472368 |
0.9338 | High Similarity | NPC147686 |
0.9338 | High Similarity | NPC471620 |
0.9338 | High Similarity | NPC118813 |
0.9333 | High Similarity | NPC13408 |
0.9333 | High Similarity | NPC472367 |
0.9333 | High Similarity | NPC476333 |
0.9333 | High Similarity | NPC254741 |
0.9333 | High Similarity | NPC240593 |
0.9328 | High Similarity | NPC172262 |
0.9328 | High Similarity | NPC103842 |
0.9313 | High Similarity | NPC60558 |
0.9291 | High Similarity | NPC266572 |
0.9291 | High Similarity | NPC168085 |
0.9291 | High Similarity | NPC139364 |
0.9291 | High Similarity | NPC194653 |
0.9291 | High Similarity | NPC203747 |
0.9291 | High Similarity | NPC254702 |
0.9291 | High Similarity | NPC80710 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC209560 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.9847 | High Similarity | NPD1510 | Phase 2 |
0.9542 | High Similarity | NPD1240 | Approved |
0.9398 | High Similarity | NPD1607 | Approved |
0.9338 | High Similarity | NPD1549 | Phase 2 |
0.9265 | High Similarity | NPD1550 | Clinical (unspecified phase) |
0.9265 | High Similarity | NPD1552 | Clinical (unspecified phase) |
0.9214 | High Similarity | NPD4378 | Clinical (unspecified phase) |
0.9191 | High Similarity | NPD2796 | Approved |
0.9028 | High Similarity | NPD4380 | Phase 2 |
0.8944 | High Similarity | NPD7410 | Clinical (unspecified phase) |
0.8776 | High Similarity | NPD1934 | Approved |
0.8741 | High Similarity | NPD1511 | Approved |
0.8716 | High Similarity | NPD2393 | Clinical (unspecified phase) |
0.8707 | High Similarity | NPD7411 | Suspended |
0.8667 | High Similarity | NPD4381 | Clinical (unspecified phase) |
0.8667 | High Similarity | NPD7075 | Discontinued |
0.8662 | High Similarity | NPD3750 | Approved |
0.8662 | High Similarity | NPD1878 | Clinical (unspecified phase) |
0.8658 | High Similarity | NPD8443 | Clinical (unspecified phase) |
0.8652 | High Similarity | NPD970 | Clinical (unspecified phase) |
0.8621 | High Similarity | NPD1512 | Approved |
0.8611 | High Similarity | NPD6799 | Approved |
0.8591 | High Similarity | NPD2801 | Approved |
0.8591 | High Similarity | NPD7819 | Suspended |
0.8591 | High Similarity | NPD7096 | Clinical (unspecified phase) |
0.8523 | High Similarity | NPD6801 | Discontinued |
0.8511 | High Similarity | NPD1551 | Phase 2 |
0.8477 | Intermediate Similarity | NPD3882 | Suspended |
0.8389 | Intermediate Similarity | NPD6599 | Discontinued |
0.838 | Intermediate Similarity | NPD2935 | Discontinued |
0.8355 | Intermediate Similarity | NPD7768 | Phase 2 |
0.8333 | Intermediate Similarity | NPD7421 | Clinical (unspecified phase) |
0.8333 | Intermediate Similarity | NPD7852 | Clinical (unspecified phase) |
0.831 | Intermediate Similarity | NPD3748 | Approved |
0.8301 | Intermediate Similarity | NPD3749 | Approved |
0.8298 | Intermediate Similarity | NPD6651 | Approved |
0.8289 | Intermediate Similarity | NPD3817 | Phase 2 |
0.8286 | Intermediate Similarity | NPD943 | Approved |
0.8273 | Intermediate Similarity | NPD6859 | Clinical (unspecified phase) |
0.8248 | Intermediate Similarity | NPD2798 | Approved |
0.8228 | Intermediate Similarity | NPD3818 | Discontinued |
0.8217 | Intermediate Similarity | NPD6167 | Clinical (unspecified phase) |
0.8217 | Intermediate Similarity | NPD6166 | Phase 2 |
0.8217 | Intermediate Similarity | NPD6168 | Clinical (unspecified phase) |
0.8207 | Intermediate Similarity | NPD2800 | Approved |
0.8207 | Intermediate Similarity | NPD1243 | Approved |
0.8194 | Intermediate Similarity | NPD2344 | Approved |
0.8188 | Intermediate Similarity | NPD920 | Approved |
0.8188 | Intermediate Similarity | NPD5403 | Approved |
0.8182 | Intermediate Similarity | NPD1509 | Clinical (unspecified phase) |
0.8176 | Intermediate Similarity | NPD5401 | Approved |
0.8176 | Intermediate Similarity | NPD7804 | Clinical (unspecified phase) |
0.8163 | Intermediate Similarity | NPD643 | Clinical (unspecified phase) |
0.8141 | Intermediate Similarity | NPD6959 | Discontinued |
0.8089 | Intermediate Similarity | NPD6232 | Discontinued |
0.8063 | Intermediate Similarity | NPD7054 | Approved |
0.8054 | Intermediate Similarity | NPD642 | Clinical (unspecified phase) |
0.8054 | Intermediate Similarity | NPD2532 | Approved |
0.8054 | Intermediate Similarity | NPD2534 | Approved |
0.8054 | Intermediate Similarity | NPD2533 | Approved |
0.805 | Intermediate Similarity | NPD7473 | Discontinued |
0.8043 | Intermediate Similarity | NPD1203 | Approved |
0.8015 | Intermediate Similarity | NPD1547 | Clinical (unspecified phase) |
0.8014 | Intermediate Similarity | NPD2313 | Discontinued |
0.8012 | Intermediate Similarity | NPD7074 | Phase 3 |
0.8012 | Intermediate Similarity | NPD7472 | Approved |
0.8 | Intermediate Similarity | NPD4868 | Clinical (unspecified phase) |
0.7985 | Intermediate Similarity | NPD1548 | Phase 1 |
0.7975 | Intermediate Similarity | NPD4419 | Clinical (unspecified phase) |
0.7973 | Intermediate Similarity | NPD2309 | Approved |
0.7963 | Intermediate Similarity | NPD5953 | Discontinued |
0.7963 | Intermediate Similarity | NPD6797 | Phase 2 |
0.7962 | Intermediate Similarity | NPD5494 | Approved |
0.7935 | Intermediate Similarity | NPD5402 | Approved |
0.7931 | Intermediate Similarity | NPD2799 | Discontinued |
0.7914 | Intermediate Similarity | NPD7251 | Discontinued |
0.7905 | Intermediate Similarity | NPD4628 | Phase 3 |
0.7883 | Intermediate Similarity | NPD1610 | Phase 2 |
0.7872 | Intermediate Similarity | NPD6832 | Phase 2 |
0.7872 | Intermediate Similarity | NPD4908 | Phase 1 |
0.7866 | Intermediate Similarity | NPD7808 | Phase 3 |
0.7852 | Intermediate Similarity | NPD9545 | Approved |
0.784 | Intermediate Similarity | NPD7286 | Phase 2 |
0.7838 | Intermediate Similarity | NPD2654 | Approved |
0.7836 | Intermediate Similarity | NPD9493 | Approved |
0.7829 | Intermediate Similarity | NPD6980 | Clinical (unspecified phase) |
0.7826 | Intermediate Similarity | NPD3972 | Approved |
0.7826 | Intermediate Similarity | NPD9717 | Approved |
0.7808 | Intermediate Similarity | NPD4308 | Phase 3 |
0.7808 | Intermediate Similarity | NPD7033 | Discontinued |
0.7805 | Intermediate Similarity | NPD6559 | Discontinued |
0.7785 | Intermediate Similarity | NPD919 | Approved |
0.7762 | Intermediate Similarity | NPD4907 | Clinical (unspecified phase) |
0.7762 | Intermediate Similarity | NPD3268 | Approved |
0.7758 | Intermediate Similarity | NPD4338 | Clinical (unspecified phase) |
0.7755 | Intermediate Similarity | NPD6099 | Approved |
0.7755 | Intermediate Similarity | NPD6100 | Approved |
0.7754 | Intermediate Similarity | NPD422 | Phase 1 |
0.7748 | Intermediate Similarity | NPD7390 | Discontinued |
0.7727 | Intermediate Similarity | NPD3226 | Approved |
0.7724 | Intermediate Similarity | NPD230 | Phase 1 |
0.7688 | Intermediate Similarity | NPD1247 | Approved |
0.766 | Intermediate Similarity | NPD2797 | Approved |
0.766 | Intermediate Similarity | NPD1470 | Approved |
0.7639 | Intermediate Similarity | NPD3764 | Approved |
0.7626 | Intermediate Similarity | NPD1201 | Approved |
0.7622 | Intermediate Similarity | NPD5844 | Phase 1 |
0.7613 | Intermediate Similarity | NPD7458 | Discontinued |
0.7603 | Intermediate Similarity | NPD1899 | Clinical (unspecified phase) |
0.7595 | Intermediate Similarity | NPD4288 | Approved |
0.7593 | Intermediate Similarity | NPD3926 | Phase 2 |
0.7589 | Intermediate Similarity | NPD3225 | Approved |
0.7589 | Intermediate Similarity | NPD1876 | Approved |
0.7584 | Intermediate Similarity | NPD2346 | Discontinued |
0.7568 | Intermediate Similarity | NPD651 | Clinical (unspecified phase) |
0.755 | Intermediate Similarity | NPD6398 | Clinical (unspecified phase) |
0.7535 | Intermediate Similarity | NPD3267 | Approved |
0.7535 | Intermediate Similarity | NPD1164 | Approved |
0.7535 | Intermediate Similarity | NPD3266 | Approved |
0.7534 | Intermediate Similarity | NPD4307 | Phase 2 |
0.7532 | Intermediate Similarity | NPD1465 | Phase 2 |
0.753 | Intermediate Similarity | NPD7993 | Clinical (unspecified phase) |
0.7514 | Intermediate Similarity | NPD4363 | Phase 3 |
0.7514 | Intermediate Similarity | NPD4360 | Phase 2 |
0.7483 | Intermediate Similarity | NPD1933 | Approved |
0.7481 | Intermediate Similarity | NPD1241 | Discontinued |
0.7471 | Intermediate Similarity | NPD4361 | Phase 2 |
0.7471 | Intermediate Similarity | NPD4362 | Clinical (unspecified phase) |
0.7448 | Intermediate Similarity | NPD3027 | Phase 3 |
0.7447 | Intermediate Similarity | NPD1608 | Approved |
0.7434 | Intermediate Similarity | NPD7003 | Approved |
0.7431 | Intermediate Similarity | NPD9494 | Approved |
0.7429 | Intermediate Similarity | NPD8090 | Clinical (unspecified phase) |
0.7423 | Intermediate Similarity | NPD5711 | Approved |
0.7423 | Intermediate Similarity | NPD5710 | Approved |
0.7415 | Intermediate Similarity | NPD1612 | Clinical (unspecified phase) |
0.7415 | Intermediate Similarity | NPD1613 | Approved |
0.7403 | Intermediate Similarity | NPD6143 | Clinical (unspecified phase) |
0.74 | Intermediate Similarity | NPD5404 | Approved |
0.74 | Intermediate Similarity | NPD5408 | Approved |
0.74 | Intermediate Similarity | NPD5406 | Approved |
0.74 | Intermediate Similarity | NPD5405 | Approved |
0.7397 | Intermediate Similarity | NPD411 | Approved |
0.7397 | Intermediate Similarity | NPD1296 | Phase 2 |
0.7379 | Intermediate Similarity | NPD1529 | Clinical (unspecified phase) |
0.7375 | Intermediate Similarity | NPD2296 | Approved |
0.7365 | Intermediate Similarity | NPD447 | Suspended |
0.7365 | Intermediate Similarity | NPD1729 | Discontinued |
0.7365 | Intermediate Similarity | NPD5124 | Phase 1 |
0.7365 | Intermediate Similarity | NPD5123 | Clinical (unspecified phase) |
0.7361 | Intermediate Similarity | NPD1019 | Discontinued |
0.7355 | Intermediate Similarity | NPD7004 | Clinical (unspecified phase) |
0.731 | Intermediate Similarity | NPD1530 | Clinical (unspecified phase) |
0.7299 | Intermediate Similarity | NPD7879 | Clinical (unspecified phase) |
0.7296 | Intermediate Similarity | NPD7615 | Clinical (unspecified phase) |
0.7283 | Intermediate Similarity | NPD4287 | Approved |
0.7279 | Intermediate Similarity | NPD6798 | Discontinued |
0.7278 | Intermediate Similarity | NPD6104 | Discontinued |
0.7273 | Intermediate Similarity | NPD4379 | Clinical (unspecified phase) |
0.725 | Intermediate Similarity | NPD6844 | Discontinued |
0.7246 | Intermediate Similarity | NPD3751 | Discontinued |
0.7239 | Intermediate Similarity | NPD74 | Approved |
0.7239 | Intermediate Similarity | NPD9266 | Approved |
0.7237 | Intermediate Similarity | NPD1471 | Phase 3 |
0.7237 | Intermediate Similarity | NPD2343 | Clinical (unspecified phase) |
0.7234 | Intermediate Similarity | NPD17 | Approved |
0.7229 | Intermediate Similarity | NPD7784 | Clinical (unspecified phase) |
0.7211 | Intermediate Similarity | NPD4625 | Phase 3 |
0.7207 | Intermediate Similarity | NPD7501 | Clinical (unspecified phase) |
0.7194 | Intermediate Similarity | NPD405 | Clinical (unspecified phase) |
0.7188 | Intermediate Similarity | NPD5890 | Approved |
0.7188 | Intermediate Similarity | NPD5889 | Approved |
0.717 | Intermediate Similarity | NPD5808 | Clinical (unspecified phase) |
0.7164 | Intermediate Similarity | NPD9267 | Approved |
0.7164 | Intermediate Similarity | NPD9265 | Clinical (unspecified phase) |
0.7164 | Intermediate Similarity | NPD9264 | Approved |
0.7164 | Intermediate Similarity | NPD9263 | Approved |
0.7163 | Intermediate Similarity | NPD4196 | Clinical (unspecified phase) |
0.7161 | Intermediate Similarity | NPD2354 | Approved |
0.7158 | Intermediate Similarity | NPD7584 | Approved |
0.7153 | Intermediate Similarity | NPD4749 | Approved |
0.7152 | Intermediate Similarity | NPD7199 | Phase 2 |
0.7143 | Intermediate Similarity | NPD6280 | Approved |
0.7143 | Intermediate Similarity | NPD37 | Approved |
0.7143 | Intermediate Similarity | NPD6279 | Approved |
0.7134 | Intermediate Similarity | NPD7447 | Phase 1 |
0.7134 | Intermediate Similarity | NPD4661 | Approved |
0.7134 | Intermediate Similarity | NPD4662 | Approved |
0.7133 | Intermediate Similarity | NPD6355 | Discontinued |
0.7108 | Intermediate Similarity | NPD7229 | Phase 3 |
0.7103 | Intermediate Similarity | NPD1283 | Approved |
0.7092 | Intermediate Similarity | NPD1894 | Discontinued |
0.7086 | Intermediate Similarity | NPD8397 | Clinical (unspecified phase) |
0.7083 | Intermediate Similarity | NPD9269 | Phase 2 |
0.7083 | Intermediate Similarity | NPD1481 | Phase 2 |
0.7075 | Intermediate Similarity | NPD2861 | Phase 2 |
0.7073 | Intermediate Similarity | NPD6971 | Discontinued |
0.707 | Intermediate Similarity | NPD7213 | Phase 3 |
0.707 | Intermediate Similarity | NPD7212 | Phase 2 |
0.7067 | Intermediate Similarity | NPD3140 | Approved |
Bioactivity similarity was calculated based on bioactivity descriptors of compounds. The bioactivity descriptors were calculated by a recently developed AI algorithm Chemical Checker (CC) [Nature Biotechnology, 38:1087–1096, 2020; Nature Communications, 12:3932, 2021], which evaluated bioactivity similarities at five levels:
☉ A: chemistry similarity;
☉ B: biological targets similarity;
☉ C: networks similarity;
☉ D: cell-based bioactivity similarity;
☉ E: similarity based on clinical data.
Those 5 categories of CC bioactivity descriptors were calculated and then subjected to manifold projection using UMAP algorithm, to project all NPs on a 2-Dimensional space. The current NP was highlighted with a small circle in the 2-D map. Below figures: left-to-right, A-to-E.